MMNFQ (MedMen Enterprises) EBIT: $-137.3 Mil (TTM As of Mar. 2023)


What is MedMen Enterprises EBIT?

MedMen Enterprises MMNFQ -90.00% EBIT is $-137.3 Mil as of Mar. 2023.

MedMen Enterprises's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2023 was $-24.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2023 was $-137.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. MedMen Enterprises's annualized ROC % for the quarter that ended in Mar. 2023 was -9.35%. MedMen Enterprises's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -117.09%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

MedMen Enterprises  (OTCPK:MMNFQ) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

MedMen Enterprises's annualized ROC % for the quarter that ended in Mar. 2023 is calculated as:

ROC % (Q: Mar. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Mar. 2023 ))/ count )
=-41.092 * ( 1 - 14.67% )/( (266.076 + 484.09)/ 2 )
=-35.0638036/375.083
=-9.35 %

where

Invested Capital(Q: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=238.475 - 109.832 - ( 15.605 - max(0, 237.644 - 100.211+15.605))
=266.076

Invested Capital(Q: Mar. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=215.587 - 114.701 - ( 7.626 - max(0, 474.281 - 91.077+7.626))
=484.09

Note: The Operating Income data used here is four times the quarterly (Mar. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

MedMen Enterprises's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2022  Q: Mar. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-99.744/( ( (91.921 + max(-82.052, 0)) + (78.457 + max(-79.06, 0)) )/ 2 )
=-99.744/( ( 91.921 + 78.457 )/ 2 )
=-99.744/85.189
=-117.09 %

where Working Capital is:

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.416 + 13.675 + 54.015) - (109.832 + 0.567 + 44.759)
=-82.052

Working Capital(Q: Mar. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.862 + 14.669 + 64.92) - (114.701 + 0.567 + 47.243)
=-79.06

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

MedMen Enterprises's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2023 )
=-137.258/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedMen Enterprises EBIT Related Terms

MedMen Enterprises EBIT Historical Data

* Premium members only.

The historical data trend for MedMen Enterprises's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedMen Enterprises EBIT Chart

MedMen Enterprises Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -94.61 -242.34 -458.57 -69.75 -132.38

MedMen Enterprises Quarterly Data
Apr18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.33 -103.10 -6.43 -2.80 -24.94

MMNFQ vs ZTS, VTRS, NBIX: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, MedMen Enterprises's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MedMen Enterprises EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MedMen Enterprises's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where MedMen Enterprises's EV-to-EBIT falls into.


MedMen Enterprises EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-137.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-137.3 Mil mean?
MedMen Enterprises (MMNFQ) has a EBIT of $-137.3 Mil as of Mar. 2023. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on MedMen Enterprises.
Is MedMen Enterprises' EBIT too high?
MedMen Enterprises' current EBIT is $-137.3 Mil.
How does MedMen Enterprises' EBIT compare to ZTS and VTRS?
MedMen Enterprises' EBIT of $-137.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on MedMen Enterprises. MedMen Enterprises's current EBIT is $-137.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedMen Enterprises stock overvalued right now?
MedMen Enterprises (MMNFQ) has a current EBIT of $-137.3 Mil. The current EBIT is $-137.3 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For MedMen Enterprises (MMNFQ), the current EBIT is $-137.3 Mil as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MedMen Enterprises Business Description

Address 8740 S Sepulveda Boulevard, Suite 105, Los Angeles, CA, USA, 90045
MedMen Enterprises Inc is a American cannabis company dedicated to improving life with Cannabis for All. With operations across the United States in California, Nevada, Illinois, Arizona, Massachusetts, and New York, the company has MedMen and LuxLyte brands offering cannabis in consumer-preferred product forms for medical and recreational use. It produces and curates the consumer product assortment for retail operations in its local communities, and drives consumer loyalty with service and engaging in-store experience, combined with reward, delivery, and e-commerce programs.